Moreover, molecular and genetic features, including germline and somatic breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) mutations [34,35], may influence the prognosis of patients [36,37], the recurrence rate [38], and the cancer response to DNA-damaging agents, such as platinum chemotherapy [39], or DNA repair pathways inhibitors. The gene discussed is BRCA2; the disease is breast carcinoma.